RxDoctor Payments Data

John Craig, MD

Family Medicine · Minden, NENPI 1477999423

Payments from drug & device makers

$1,565in general payments, 2019–2025

Across 103 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$325
  • Amgen$211
  • Johnson & Johnson$159
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$154
  • Lilly USA, LLC$151
  • Pfizer$125
  • plus $440 from 18 others

What the payments were for

  • Food & beverage$1,565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,565 in reported general payments places this provider in the 70th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$4,707
Medicare patients
13
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$103,551
XareltoRivaroxaban136$69,782
JardianceEmpagliflozin109$51,546
XifaxanRifaximin25$35,786
Spiriva RespimatTiotropium Bromide35$19,109
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$18,906
EntrestoSacubitril/Valsartan28$17,420
OzempicSemaglutide14$13,996
KerendiaFinerenone22$13,996
MyrbetriqMirabegron29$13,138
BelsomraSuvorexant24$10,647
LinzessLinaclotide19$9,919
RybelsusSemaglutide11$9,823
Victoza 2-PakLiraglutide14$7,483
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$103,551176 claims
Boehringer IngelheimJardiance, Spiriva Respimat$14$70,655144 claims
Johnson & JohnsonXarelto$159$69,782136 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$154$35,78625 claims
Novo NordiskOzempic, Rybelsus$325$23,81925 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Incruse Ellipta, Shingrix$12$23,08161 claims
NovartisEntresto$84$17,42028 claims
BayerKerendia$24$13,99622 claims
MerckBelsomra$34$10,64724 claims
AbbVieLinzess$18$9,91919 claims
AstraZenecaBrilinta$12$5,54712 claims
Sanofi-aventis U.S. LLCLantus$22$2,61240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Minden

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →